
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. has demonstrated a strong positive outlook, as evidenced by its raised full-year 2025 pro forma net revenue guidance to a range of $390–$410 million, highlighting robust adoption of its product, DefenCath. The company's fourth-quarter net revenue is anticipated to fall between $115 million and $135 million, which reinforces the momentum toward year-end and reflects greater utilization among outpatient dialysis customers. Additionally, the increased fully synergized pro forma adjusted EBITDA guidance of $220–$240 million further underscores the strong financial performance and operational execution of the company.
Bears say
Cormedix Inc is facing significant challenges related to the uncertainty surrounding the TDAPA pricing, which could negatively impact its financial performance in the near term. Although there is potential for growth through the commercialization of DefenCath and an estimated opportunity valued between $100 million to $200 million, the success of this initiative hinges on overcoming the current pricing headwinds. The company's reliance on a single product and geographic region amplifies these risks, indicating a concerning outlook for its financial stability.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares